1. Home
  2. HERZ vs GRDX Comparison

HERZ vs GRDX Comparison

Compare HERZ & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Herzfeld Credit Income Fund Inc.

HERZ

Herzfeld Credit Income Fund Inc.

SELL

Current Price

$13.15

Market Cap

30.4M

Sector

Finance

ML Signal

SELL

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

HOLD

Current Price

$2.54

Market Cap

33.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HERZ
GRDX
Founded
N/A
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4M
33.2M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
HERZ
GRDX
Price
$13.15
$2.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.7K
★ 134.0K
Earning Date
N/A
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.62
$1.87
52 Week High
$19.30
$6.93

Technical Indicators

Market Signals
Indicator
HERZ
GRDX
Relative Strength Index (RSI) 33.14 29.44
Support Level N/A N/A
Resistance Level $16.98 $2.73
Average True Range (ATR) 0.32 0.83
MACD 0.00 -0.33
Stochastic Oscillator 27.69 0.00

Price Performance

Historical Comparison
HERZ
GRDX

About HERZ Herzfeld Credit Income Fund Inc.

Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: